GlassScriptPhysician profile
Howard M Robinson
NPI 1942374657
$1,555.37
in general payments reported to CMS, 2019-2025
22 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $394 · 2021: $183 · 2022: $147 · 2023: $182 · 2024: $298 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $581.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $219.94 | 2019-2021 | |
| Lilly USA, LLC | $201.21 | 2020-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $144.11 | 2019-2024 | Airsupra, Breztri |
| Edwards Lifesciences Corporation | $100.93 | 2025 | Sapien 3 Ultra Resilia |
| Janssen Biotech, INC. | $85.89 | 2019-2021 | |
| Abbvie INC. | $85.03 | 2021-2022 | |
| Exact Sciences Corporation | $84.96 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $80.66 | 2020 | |
| Merck Sharp & Dohme LLC | $73.24 | 2019-2020 | |
| Theratechnologies INC. | $68.91 | 2019-2021 | |
| Novo Nordisk INC | $66.64 | 2020-2023 | Rybelsus, Ozempic |
| Paratek Pharmaceuticals, INC. | $50.07 | 2019-2021 | |
| Abbott Laboratories | $44.94 | 2019-2022 | |
| Orexo US, INC. | $38.63 | 2020-2023 | Zubsolv |
| Intuity Medical INC | $38.17 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $31.22 | 2020 | |
| Amarin Pharma, INC. | $30.40 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $27.93 | 2022-2023 | Quviviq |
| Insmed, INC. | $24.30 | 2020 | |
| Lucid Diagnostics INC. | $23.08 | 2024 | |
| Amgen INC. | $18.08 | 2024 | Repatha, Otezla |
| Actelion Pharmaceuticals US, INC. | $17.03 | 2024 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.